Siren Biotechnology announced it raised $19.6 Million in an initial filing from an offering of $32.4 Million

Company

Location

About

The fight against cancer needs new, big, bold ideas. At Siren, we’ve got one: Universal AAV Immuno-Gene Therapy. We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.